Hospira Reports First-Quarter 20...(-------- -------- Total Sharehold...),Health

Date:4/28/2009

-------- -------- Total Shareholders' Equity 1,941.9 1,776.4 -------- -------- Total Liabilities and Shareholders' Equity $5,085.7 $5,074.1 ======== ======== Hospira, Inc. Condensed Consolidated Statements of Cash Flows (Unaudited) (dollars in millions) Three Months Ended March 31, ----------------- 2009 2008 ------ ------ Cash Flow From Operating Activities: Net income $165.5 $65.4 Adjustments to reconcile net income to net cash from operating activities- Depreciation 41.2 47.1 Amortization of intangible assets 14.7 16.9 Stock-based compensation expense 13.1 14.4 Deferred income tax and other tax adjustments (89.4) (11.5) Changes in assets and liabilities- Trade receivables 20.0 (13.6) Inventories (11.5) (24.8) Prepaid expenses and other assets (13.1) 11.4 Trade accounts payable (14.2) 6.1 Other liabilities (41.7) (47.8) Other, net 4.7
'/>"/>

SOURCE Hospira, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
Related medicine news :

1. Hospira to Host Conference Call for First-Quarter 2009 Results
2. Hospira to Present at Cowen and Companys 29th Annual Health Care Conference March 17
3. Hospira Expands Board of Directors
4. Hospira Reports Fourth-Quarter and Full-Year 2008 Results
5. Hospiras Precedex(R) Phase IV Study Published in the Journal of the American Medical Association
6. Hospira to Host Conference Call for Fourth-Quarter 2008 Results and 2009 Projections
7. Hospira to Present at J.P. Morgans 27th Annual Healthcare Conference January 14
8. Hospira Names Ken Meyers to Lead Human Resources
9. Hospira Reports Third-Quarter 2008 Results
10. Hospira to Present at the 2008 Annual Credit Suisse Health Care Conference on November 12
11. FDA Approves New Indication for Hospiras Precedex (Dexmedetomidine HCL) Injection